CYP3A4 and hepatocellular carcinoma: In conclusion, this case report underscores the significance of acknowledging the potential pharmacokinetic interaction involving CYP3A4 and P-gp inhibition by regorafenib in LT recipients with recurrent HCC undergoing treatment with regorafenib and sirolimus.